Dr. Graff on the KEYNOTE-641 Trial in mCRPC

Video

Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute, discusses the phase III KEYNOTE-641 trial in metastatic castration-resistant prostate cancer (mCRPC).

Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute, discusses the phase III KEYNOTE-641 trial in metastatic castration-resistant prostate cancer (mCRPC).

At the 2020 Genitourinary Cancers Symposium, data from cohorts 4 and 5 of the phase II KEYNOTE-199 trial demonstrated that the addition of pembrolizumab (Keytruda) to enzalutamide (Xtandi) resulted in moderate activity in patients with chemotherapy-naïve mCRPC who progressed on enzalutamide.

Accordingly, Merck has launched the phase III KEYNOTE-641 trial, in which patients with mCRPC will be randomized to receive either enzalutamide plus placebo or enzalutamide plus pembrolizumab to determine whether the addition of pembrolizumab extends overall survival, concludes Graff.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute